Novavax (NVAX) Tops Q1 EPS by $3.36

Novavax (NASDAQ: NVAX) reported Q1 EPS of $2.93, $3.36 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $667 million versus the consensus estimate of $251.8 million.

GUIDANCE:

Novavax sees FY2025 revenue of $975-1025 million.

Financial Framework

Reiterates Full Year 2025 Financial Guidance

Novavax is reiterating Full Year 2025 Financial Guidance for combined R&D and SG&A expenses and currently expects to achieve the following results:

Raises Full Year 2025 Revenue Framework

Novavax transitioned lead commercial responsibility of Nuvaxovid beginning with the 2025-2026 vaccination season to Sanofi for select markets. Since Novavax is reliant on Sanofi's sales forecasts for certain revenue components, these are not included in the Full Year 2025 Revenue Framework. For 2025, Novavax currently expects to achieve Adjusted Total Revenue¹ of between $975 million and $1,025 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• A. O. Smith CEO Stephen Shafer named chairman